Nour Abdallah, Andrew Elliott, Norm Smith, Stephanie M Stanford, Neeraj Agarwal, Aditya Bagrodia, Rohan Garje, Nunzio Bottini, Rana R McKay
{"title":"Dissecting the Significance of Acid Phosphatase 1 Gene Alterations in Prostate Cancer.","authors":"Nour Abdallah, Andrew Elliott, Norm Smith, Stephanie M Stanford, Neeraj Agarwal, Aditya Bagrodia, Rohan Garje, Nunzio Bottini, Rana R McKay","doi":"10.1200/PO-24-00444","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The acid phosphatase 1 (<i>ACP1</i>) gene encodes low-molecular-weight protein tyrosine phosphatase, which is overexpressed in prostate cancer (PC) and a potential therapeutic target. We analyzed <i>ACP1</i> expression in primary/metastatic PC and its association with molecular profiles and clinical outcomes.</p><p><strong>Methods: </strong>NextGen sequencing of DNA (592-gene/whole-exome sequencing)/RNA(whole-transcriptome sequencing) was performed for 5,028 specimens. <i>ACP1</i>-High/<i>ACP1</i>-Low expression was defined as quartile (Q4/1) of RNA transcripts per million (TPM). DNA mutational profiles were analyzed for <i>ACP1</i>-quartile-stratified samples. Gene set enrichment analysis was used for Hallmark collection of pathways. PD-L1+(≥2+, ≥5%; SP142) was tested by immunohistochemistry. Tumor microenvironment's (TME) immune cell fractions were estimated by RNA deconvolution/quanTIseq. Overall survival (OS) was assessed from initial diagnosis/treatment initiation to death/last follow-up.</p><p><strong>Results: </strong>We included 3,058 (60.8%) samples from the prostate, 634 (12.6%) from lymph node metastases (LNMs), and 1,307 (26.0%) from distant metastases (DMs). <i>ACP1</i> expression was higher in LNM/DM than prostate (49.8/47.9 <i>v</i> 44.1 TPM; <i>P</i> < .0001). <i>TP53</i> mutations were enriched in <i>ACP1</i>-Q4 (37.9%[Q4] <i>v</i> 27.0%[Q1]; <i>P</i> < .001) among prostate samples. Pathways associated with cell cycle regulation and oxidative phosphorylation were enriched in <i>ACP1</i>-Q4, whereas epithelial-mesenchymal transition and tumor necrosis factor-alpha signaling via nuclear factor kappa-light-chain-enhancer of activated B-cell pathways were enriched in <i>ACP1</i>-Q1. Neuroendocrine and androgen receptor signaling was increased in <i>ACP1</i>-Q4. M2 macrophages and natural killer cell fractions were increased, whereas T cells and M1 macrophages were decreased in <i>ACP1</i>-Q4. While OS differences between <i>ACP1</i>-Q1/Q4 were not statistically significant, there was a trend for worse OS among <i>ACP1</i>-Q4 prostate samples (Q4 <i>v</i> Q1: hazard ratio [HR], 1.19 [95% CI, 0.99 to 1.42]; <i>P</i> = .06) and DM (HR, 1.12 [95% CI, 0.93 to 1.36]; <i>P</i> = .22) but not LNM (HR, 0.98 [95% CI, 0.74 to 1.29]; <i>P</i> = .87).</p><p><strong>Conclusion: </strong>ACP1-High tumors exhibit a distinct molecular profile and cold TME, highlighting <i>ACP1</i>'s potential role in PC pathogenesis and novel therapeutic targeting.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"8 ","pages":"e2400444"},"PeriodicalIF":5.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO precision oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/PO-24-00444","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The acid phosphatase 1 (ACP1) gene encodes low-molecular-weight protein tyrosine phosphatase, which is overexpressed in prostate cancer (PC) and a potential therapeutic target. We analyzed ACP1 expression in primary/metastatic PC and its association with molecular profiles and clinical outcomes.
Methods: NextGen sequencing of DNA (592-gene/whole-exome sequencing)/RNA(whole-transcriptome sequencing) was performed for 5,028 specimens. ACP1-High/ACP1-Low expression was defined as quartile (Q4/1) of RNA transcripts per million (TPM). DNA mutational profiles were analyzed for ACP1-quartile-stratified samples. Gene set enrichment analysis was used for Hallmark collection of pathways. PD-L1+(≥2+, ≥5%; SP142) was tested by immunohistochemistry. Tumor microenvironment's (TME) immune cell fractions were estimated by RNA deconvolution/quanTIseq. Overall survival (OS) was assessed from initial diagnosis/treatment initiation to death/last follow-up.
Results: We included 3,058 (60.8%) samples from the prostate, 634 (12.6%) from lymph node metastases (LNMs), and 1,307 (26.0%) from distant metastases (DMs). ACP1 expression was higher in LNM/DM than prostate (49.8/47.9 v 44.1 TPM; P < .0001). TP53 mutations were enriched in ACP1-Q4 (37.9%[Q4] v 27.0%[Q1]; P < .001) among prostate samples. Pathways associated with cell cycle regulation and oxidative phosphorylation were enriched in ACP1-Q4, whereas epithelial-mesenchymal transition and tumor necrosis factor-alpha signaling via nuclear factor kappa-light-chain-enhancer of activated B-cell pathways were enriched in ACP1-Q1. Neuroendocrine and androgen receptor signaling was increased in ACP1-Q4. M2 macrophages and natural killer cell fractions were increased, whereas T cells and M1 macrophages were decreased in ACP1-Q4. While OS differences between ACP1-Q1/Q4 were not statistically significant, there was a trend for worse OS among ACP1-Q4 prostate samples (Q4 v Q1: hazard ratio [HR], 1.19 [95% CI, 0.99 to 1.42]; P = .06) and DM (HR, 1.12 [95% CI, 0.93 to 1.36]; P = .22) but not LNM (HR, 0.98 [95% CI, 0.74 to 1.29]; P = .87).
Conclusion: ACP1-High tumors exhibit a distinct molecular profile and cold TME, highlighting ACP1's potential role in PC pathogenesis and novel therapeutic targeting.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
